Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech (NYSE American: AIM) announced the granting of a utility patent by the Netherlands Patent Office for its double-stranded RNA product, rugged dsRNA, linked to Ampligen® (rintatolimod). This patent extends AIM's portfolio for COVID-19 treatments. Ampligen is designed to enhance the immune system's response, showing significant impact on SARS-CoV-2 viral replication. The company is also conducting early access programs and Phase 2 clinical studies for Ampligen in pancreatic cancer, alongside ongoing trials for various solid tumors.

AIM ImmunoTech Inc. (NYSE American: AIM) announced a live video webcast presentation by CEO Thomas K. Equels at the Virtual Investor 2023 Companies to Watch Event on January 18, 2023, at 11:00 AM ET. The company focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. Its leading product, Ampligen®, is currently in clinical trials for pancreatic cancer and approved for treating chronic fatigue syndrome in Argentina. A replay of the webcast will be available on the company’s website for 90 days.

AIM ImmunoTech (NYSE American: AIM) has promoted Christopher McAleer, Ph.D., to Scientific Officer, reflecting his contributions since joining as Deputy Scientific Officer in June 2022. CEO Thomas K. Equels emphasized McAleer's vital role in advancing AIM's clinical development programs, particularly with the drug Ampligen. McAleer brings extensive experience from his previous role at Hesperos, where he significantly increased operational scale. AIM's Ampligen is currently in clinical trials for various cancers and approved for use in treating severe chronic fatigue syndrome.

AIM ImmunoTech (AIM) recently presented data at the British Society for Immunology Congress 2022 regarding the safety and efficacy of its intranasal treatment, Ampligen (rintatolimod). The study found that Ampligen was well-tolerated among healthy subjects, with no severe adverse events reported. The treatment potentially inhibits respiratory viruses, including SARS-CoV-2. Results indicated positive immune responses and support further development of Ampligen as a prophylactic option for respiratory infections.

AIM ImmunoTech Inc. (NYSE American: AIM) announced its abstract acceptance for poster presentation at the British Society for Immunology Congress 2022, scheduled for December 5-8, 2022, in Liverpool, UK. The poster, titled Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen, will be presented by Lisanne C.A. Smidt on December 7. Ampligen is currently in clinical trials for various conditions, including pancreatic cancer and COVID-19-related syndromes.

AIM ImmunoTech Inc. (NYSE American: AIM) reported its Q3 2022 financial results, noting a cash position of $36.7 million, sufficient for operations through 2023. The company is advancing multiple clinical studies for its lead product, Ampligen (rintatolimod), targeting various cancers and ailments, including COVID-19. Key updates include positive trial data for Ampligen in triple-negative breast cancer and FDA clearance for a Phase 2 study on post-COVID conditions. AIM is focused on reaching clinical milestones while managing operating losses, which increased to $6.4 million in Q3 2022.

AIM ImmunoTech Inc. (AIM) announced positive data from a Phase 1 study of Ampligen as part of a CKM regimen for early-stage triple negative breast cancer (TNBC). Results presented at the SITC 37th Annual Meeting show a pathologic complete response (pCR) rate of 56%, comparable to pembrolizumab-based treatments. The regimen, combining Ampligen, interferon-α2b, and celecoxib, was well tolerated with no dose-limiting toxicities. A Phase 2 study is planned to further evaluate Ampligen's efficacy as an alternative therapy.

AIM ImmunoTech Inc. announced plans to enhance its corporate governance by adding two directors with expertise in biotechnology commercialization and diversity. The board's Compensation Committee will consult an independent compensation expert to review executive pay, responding to shareholder feedback on past advisory votes.

In the previous year, AIM achieved significant clinical milestones, including positive outcomes in pancreatic cancer and other studies involving its lead product, Ampligen. These advancements aim to further align leadership with shareholder interests and boost AIM's value.

AIM ImmunoTech Inc. (AIM) announced the re-election of all three directors at its Annual Meeting of Shareholders. Directors Stewart Appelrouth, Thomas Equels, and William Mitchell received unanimous support. The company expressed gratitude towards shareholders and reaffirmed its commitment to advancing its lead drug, Ampligen, into oncology for long-term shareholder value. Ampligen is currently in clinical trials for various cancers and is approved in Argentina for chronic fatigue syndrome.